During past three decades, there has been significant process in understanding the biology and prevalence of cancer.
During past three decades, there has been significant process in understanding the biology and prevalence of cancer. Despite this cancer remains the second leading cause of deaths worldwide. It is believed that early diagnosis of cancer can improve the survival rates in cancer patients. Several diagnostic and imaging methods have been developed which are used to identify individuals with cancer. However, their widespread use has been limited due to their high price, low specificity, and ability to detect cancers only at advanced stage. To mitigate these challenges, there has been increasing interest in biomarkers as tools for cancer detection and prognosis, both as stand-alone diagnostic tools and to complement existing imaging methods and technologies.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Download Breast Cancer Antibodies Biomarkers & Clinical Trials Insight:
https://www.kuickresearch.com/ccformF.php?t=1646994975
Biomarkers are specific biological mechanisms which may exist in several forms and indicate the existence of cancer in body through their presence or activity. These processes and substances can be detected to identify the presence, risk of, and progression of cancer, as well as its response to medication. Several cancer diagnostic biomarkers have entered the market while more than 500 biomarkers are present in clinical pipeline. Among the most effective biomarkers, oncofetal biomarkers are the most peculiar and the most sensitive which are expressed in early developmental stages and in advanced cancers.
Among all the cancers, pancreatic ductal adenocarcinoma (PDAC) is most lethal whose incidences are rapidly increasing from last few years. Therefore, early detection of high-risk patients and patients with PDAC is of utmost importance. In the initial discovery phase, researchers looked for PDAC biomarkers that mimic the progression of human PDAC, focusing on proteins released from precursor lesions such as pancreatic intraepithelial neoplasia. This approach identified THBS2 as a candidate biomarker for further analysis using patient samples. Apart from this, several other diagnostic biomarkers are also present in clinical trial which are expected to enter the market during the forecast period.
Further, the introduction of artificial intelligence, deep learning, and machine learning has already transformed several sectors of science. Recently, researchers are utilizing these tools to address the challenges of cancer biomarker discovery, where the analysis of vast amounts of imaging and molecular data is beyond the ability of traditional statistical analyses and tools. Apart from this, nanotechnology is also being applied to this sector. For instance, researchers have designed nanoribbon biosensors which can be used or detecting biomarkers within the blood and plasma, suitable for precision medicine, and the aim for early and more effective diagnostics. The emergence of advanced technologies and rapid application by researchers will drive the growth of the market in forthcoming years.
The increasing prevalence of cancer and surge in demand of diagnostic biomarkers has gained interest from several pharmaceutical companies to actively invest in this sector. The major players in the market have also adopted strategic alliances to expedite the research and to maintain significant share in the global market. In 2022, Personalis announced a strategic collaboration with the Moores Cancer Center to support clinical diagnostic setting in patients with advanced solid tumors and hematological malignancies. The collaboration will bring Personalis’ leading comprehensive genomic tumor profiling test to UC San Diego health care professionals and their cancer patients to help guide FDA-approved therapy decisions, as well as clinical trial treatment options.
Recent years have seen significant advancements in the area of genomics and proteomics, which will generate new candidate markers that could be used for cancer screening. The future of cancer biomarker looks promising with opportunities in diagnostic, research, prognostic, and risk assessment. Along with this, other factors including increase in incidence of cancer and increasing research activities will also drive the growth of market during the forecast period.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com